Mazindol treatment of negative symptoms

William T. Carpenter, Alan Breier, Robert W. Buchanan, Brian Kirkpatrick, Paul Shepard, Elaine Weiner

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Hypodopaminergic and hyponoradrenergic pathophysiology may be a basis for primary and/or secondary negative symptoms in schizophrenia. The hypothesis that enhanced neurotransmission in these systems would be therapeutic for negative symptoms was tested by comparing mazindol and placebo in a double-blind, cross-over design trial. Outcome following mazindol supplementation was comparable to placebo supplementation (F(1,30) = 0.9; p = .57). Results for deficit and non-deficit schizophrenia subjects were similar, and were not affected by whether concurrent the antipsychotic drug treatment was clozapine, fluphenazine, or haloperidol. The efficacy hypothesis was not supported for either primary or secondary negative symptoms. (C) 2000 American College of Neuropsychopharmacology.

Original languageEnglish (US)
Pages (from-to)365-374
Number of pages10
JournalNeuropsychopharmacology
Volume23
Issue number4
DOIs
StatePublished - Oct 2000
Externally publishedYes

Fingerprint

Mazindol
Cross-Over Studies
Schizophrenia
Placebos
Fluphenazine
Clozapine
Haloperidol
Synaptic Transmission
Antipsychotic Agents
Therapeutics

Keywords

  • Clinical trial
  • Dopamine
  • Mazindol
  • Negative symptoms
  • Schizophrenia

ASJC Scopus subject areas

  • Pharmacology

Cite this

Carpenter, W. T., Breier, A., Buchanan, R. W., Kirkpatrick, B., Shepard, P., & Weiner, E. (2000). Mazindol treatment of negative symptoms. Neuropsychopharmacology, 23(4), 365-374. https://doi.org/10.1016/S0893-133X(00)00115-9

Mazindol treatment of negative symptoms. / Carpenter, William T.; Breier, Alan; Buchanan, Robert W.; Kirkpatrick, Brian; Shepard, Paul; Weiner, Elaine.

In: Neuropsychopharmacology, Vol. 23, No. 4, 10.2000, p. 365-374.

Research output: Contribution to journalArticle

Carpenter, WT, Breier, A, Buchanan, RW, Kirkpatrick, B, Shepard, P & Weiner, E 2000, 'Mazindol treatment of negative symptoms', Neuropsychopharmacology, vol. 23, no. 4, pp. 365-374. https://doi.org/10.1016/S0893-133X(00)00115-9
Carpenter WT, Breier A, Buchanan RW, Kirkpatrick B, Shepard P, Weiner E. Mazindol treatment of negative symptoms. Neuropsychopharmacology. 2000 Oct;23(4):365-374. https://doi.org/10.1016/S0893-133X(00)00115-9
Carpenter, William T. ; Breier, Alan ; Buchanan, Robert W. ; Kirkpatrick, Brian ; Shepard, Paul ; Weiner, Elaine. / Mazindol treatment of negative symptoms. In: Neuropsychopharmacology. 2000 ; Vol. 23, No. 4. pp. 365-374.
@article{c31217231af947c3b5be100c52b3ede7,
title = "Mazindol treatment of negative symptoms",
abstract = "Hypodopaminergic and hyponoradrenergic pathophysiology may be a basis for primary and/or secondary negative symptoms in schizophrenia. The hypothesis that enhanced neurotransmission in these systems would be therapeutic for negative symptoms was tested by comparing mazindol and placebo in a double-blind, cross-over design trial. Outcome following mazindol supplementation was comparable to placebo supplementation (F(1,30) = 0.9; p = .57). Results for deficit and non-deficit schizophrenia subjects were similar, and were not affected by whether concurrent the antipsychotic drug treatment was clozapine, fluphenazine, or haloperidol. The efficacy hypothesis was not supported for either primary or secondary negative symptoms. (C) 2000 American College of Neuropsychopharmacology.",
keywords = "Clinical trial, Dopamine, Mazindol, Negative symptoms, Schizophrenia",
author = "Carpenter, {William T.} and Alan Breier and Buchanan, {Robert W.} and Brian Kirkpatrick and Paul Shepard and Elaine Weiner",
year = "2000",
month = "10",
doi = "10.1016/S0893-133X(00)00115-9",
language = "English (US)",
volume = "23",
pages = "365--374",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Mazindol treatment of negative symptoms

AU - Carpenter, William T.

AU - Breier, Alan

AU - Buchanan, Robert W.

AU - Kirkpatrick, Brian

AU - Shepard, Paul

AU - Weiner, Elaine

PY - 2000/10

Y1 - 2000/10

N2 - Hypodopaminergic and hyponoradrenergic pathophysiology may be a basis for primary and/or secondary negative symptoms in schizophrenia. The hypothesis that enhanced neurotransmission in these systems would be therapeutic for negative symptoms was tested by comparing mazindol and placebo in a double-blind, cross-over design trial. Outcome following mazindol supplementation was comparable to placebo supplementation (F(1,30) = 0.9; p = .57). Results for deficit and non-deficit schizophrenia subjects were similar, and were not affected by whether concurrent the antipsychotic drug treatment was clozapine, fluphenazine, or haloperidol. The efficacy hypothesis was not supported for either primary or secondary negative symptoms. (C) 2000 American College of Neuropsychopharmacology.

AB - Hypodopaminergic and hyponoradrenergic pathophysiology may be a basis for primary and/or secondary negative symptoms in schizophrenia. The hypothesis that enhanced neurotransmission in these systems would be therapeutic for negative symptoms was tested by comparing mazindol and placebo in a double-blind, cross-over design trial. Outcome following mazindol supplementation was comparable to placebo supplementation (F(1,30) = 0.9; p = .57). Results for deficit and non-deficit schizophrenia subjects were similar, and were not affected by whether concurrent the antipsychotic drug treatment was clozapine, fluphenazine, or haloperidol. The efficacy hypothesis was not supported for either primary or secondary negative symptoms. (C) 2000 American College of Neuropsychopharmacology.

KW - Clinical trial

KW - Dopamine

KW - Mazindol

KW - Negative symptoms

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=0343353830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0343353830&partnerID=8YFLogxK

U2 - 10.1016/S0893-133X(00)00115-9

DO - 10.1016/S0893-133X(00)00115-9

M3 - Article

VL - 23

SP - 365

EP - 374

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 4

ER -